-+ 0.00%
-+ 0.00%
-+ 0.00%
China Accepts Hansoh Pharmaceutical's Socrodeucitinib Application for Psoriasis Treatment
Share
Listen to the news
China Accepts Hansoh Pharmaceutical's Socrodeucitinib Application for Psoriasis Treatment
  • China's National Medical Products Administration accepted Hansoh Pharmaceutical's new drug application for socrodeucitinib tablets (HS-10374) for review on November 20, 2026.
  • The treatment targets adults with moderate-to-severe plaque psoriasis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261120-12420552), on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending